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Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is
the third most common cardiovascular disease after coronary artery disease and cerebrovascular disease
and is responsible for signiﬁcant morbidity and mortality in the general population. Full dose anticoagulation
is the standard therapy for VTE, both for the acute and the long-term phase. The latest guidelines of the Amer-
ican College of Chest Physicians recommend treatment with a full-dose of unfractioned heparin (UFH), low-
molecular-weight-heparin (LMWH), fondaparinux, vitamin K antagonist (VKA) or thrombolysis for most pa-
tients with objectively conﬁrmed VTE. Catheter-guided thrombolysis and trombosuction are interventional
approaches that should be used only in selected populations; interruption of the inferior vena cava (IVC)
with a ﬁlter can be performed to prevent life-threatening PE in patients with VTE and contraindications to
anticoagulant treatment, bleeding complications during antithrombotic treatment, or VTE recurrences de-
spite optimal anticoagulation. In this review we summarize the currently available literature regarding inter-
ventional approaches for VTE treatment (vena cava ﬁlters, catheter-guided thrombolysis, thrombosuction)
and we discuss current evidences on their efﬁcacy and safety. Moreover, the appropriate indications for
their use in daily clinical practice are reviewed.
© 2011 Elsevier Ltd. All rights reserved.
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Introduction
Venous thromboembolism (VTE) consists of two related conditions:
deep vein thrombosis (DVT) and pulmonary embolism (PE). The rate of
ﬁrst-time VTE events is approximately 100 persons/100,000 population
each year in the United States, with this risk proportionally increasing
with age, from less than 5 cases/100,000 persons below the age of
15 years to 500 cases/100,000 persons above the age of 80 years [1].
The basic mechanisms underlying VTE remain those previously
described by Virchow: vascular endothelial damage, stasis of blood
ﬂow, and blood hypercoagulability; the most frequent risk factors in-
clude major surgery, trauma, hip fracture, lower extremity paralysis,
previous VTE, increasing age, cardiac or respiratory failure, prolonged
immobility, presence of central catheters, oestrogen treatment, and
several inherited and acquired hematological conditions [2].
The latest guidelines of the American College of Chest Physicians
[3] recommend treatment with a full-dose of unfractioned heparin
(UFH), low-molecular-weight-heparin (LMWH), fondaparinux, vita-
min K antagonist (VKA) or thrombolysis for most patients with objec-
tively conﬁrmed VTE. However, to prevent life-threatening PE in
patients with VTE and contraindications to anticoagulant treatment,
such as bleeding complications during antithrombotic treatment or
VTE recurrences despite optimal anticoagulation, interruption of the
inferior vena cava (IVC) with a ﬁlter should be sometimes considered
[3–7]. Likewise, catheter-guided thrombolysis and trombosuction are
interventional approaches that may be important for the manage-
ment of very selected populations.
The efﬁcacy, safety, and the appropriate indications for these ther-
apeutic approaches are discussed herein.
Inferior vena cava ﬁlters
Permanent IVC ﬁlters
Only two randomized clinical trials have evaluated the efﬁcacy
and safety of permanent IVC ﬁlters for the prevention of PE [8,9].
Decousus and colleagues randomly assigned 400 patients with prox-
imal DVT and at risk for PE to receive a vena caval ﬁlter (200 patients)
or not (200 patients), in addition to standard anticoagulant therapy
(LMWH, UFH, VKA) [8]. The rates of recurrent VTE, death, and major
bleeding were analyzed at day 12, and at two years. At day 12, two
patients assigned to receive ﬁlters (1.1 percent), as compared with
nine patients assigned to receive no ﬁlters (4.8 percent), had had symp-
tomatic or asymptomatic PE (odds ratio, 0.22; 95 percent conﬁdence
interval, 0.05 to 0.90). At two years, 37 patients assigned to the ﬁlter
group (20.8 percent), as compared with 21 patients assigned to the
no-ﬁlter group (11.6 percent), had had recurrent DVT (odds ratio,
1.87; 95 percent conﬁdence interval, 1.10 to 3.20). Therewere no signif-
icant differences inmortality or other outcomes. The authors concluded
that in high-risk patients with proximal DVT the initial beneﬁcial effect
of IVC ﬁlters for the prevention of PE was counterbalanced by an excess
of recurrent DVT, without any difference in mortality. The 8 years
follow-up data of this population showed a rate of DVT recurrences of
34.1% in patients with ﬁlter and of 27.3% in those without (p=0.08),
while the incidence of post-thrombotic syndrome was surprisingly
similar in the two groups (70.3% and 69.7%, respectively) [10].
Fullen at al enrolled in a quasi-randomised trial patients with
traumatic hip fracture to receive or not a Mobin-Uddin caval ﬁlter;
none of the patients received anticoagulant treatment [9]. The rate
of PE was 4/41 in the ﬁlter group and 19/59 in the control group
(RR 0.3, 95% CI 011 to 0.82), showing a statistically signiﬁcant reduc-
tion in the treated group; mortality was similar for ﬁlter and not-ﬁlter
patients (4/41 and 14/59, respectively; RR 0.41, 95% CI 0.15 to 1.16).
Very recently, a Cochrane review evaluated all existing published
controlled clinical trials and randomised clinical trials that examined
the efﬁcacy of ﬁlters in preventing PE [11]. Only the two above men-
tioned studies involving a total of 529 people were included [8,9] and
the authors concluded that no recommendations can be drawn. On
the one hand, one study showed a reduction in PE rates, but not in
mortality, and it was subject to signiﬁcant biases [9]. On the other
hand, the PREPIC study lacked statistical power to detect a reduction
in PE over shorter and more clinically signiﬁcant time periods and the
trial demonstrated that permanent VCFs were associated with an
increased risk of long term lower limb DVT [8].
Because of the lack of strong evidences in the literature, the latest
guidelines of the American College of Chest Physicians (ACCP) recom-
mend against the routine use of a IVC ﬁlter in addition to anticoagulants
in patients with DVT; the placement of an IVC ﬁlter is suggested only for
patients with acute proximal DVT or PE and a contraindication to antic-
oagulation because of bleeding risk [3].
Retrievable IVC ﬁlters
The vast majority of the ﬁlters which have been implanted world-
wide are of the permanent type [12–15]; nevertheless, placement of
such ﬁlters presents a number of long term complications. Decousus
and colleagues [8] demonstrated that in high-risk patients with proxi-
mal DVT the initial beneﬁt of IVC ﬁlters for the prevention of PE was
counterbalanced by an excess rate of recurrent DVT after two years of
follow-up. Moreover, one of the most important long-term complica-
tions of ﬁlters is the thrombotic occlusion of the IVC, which is reported
in 6% to 30% of cases [16,17]; other signiﬁcant complications include
vena cava perforation, ﬁlter dislocation, migration, rupture, fracture
and fragment embolization with risk of cardiac perforation and tampo-
nade [18]. Thus, alternative strategies for IVC interruption are required,
especially in patientswith a long life expectancy and forwhom the need
for anticoagulant therapy is presumably short.
Non-permanent ﬁlters are classiﬁed as temporary or retrievable
devices. Temporary ﬁlters remain attached to a wire or catheter that
exits the skin; they are often difﬁcult to manage and present frequent
complications such as thrombosis, infections or migrations [17]. They
must be removed within few days of placement, which is often not
enough to solve the clinical problem that had led to their placement.
Retrievable ﬁlters are a new generation of IVC ﬁlters and may repre-
sent a more attractive option because they may be either left in
place permanently or safely retrieved after a quite long period when
they become unnecessary [16,17]. This optimism must be tempered
by important unresolved issues, including the appropriate maximum
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implantation time, the possibility of safely and efﬁcaciously removing
the ﬁlters without being compromised by entrapped clots, and the
use of anticoagulation during the implantation and peri-removal pe-
riods. A study performed in US has recently evaluated trends in the
placement and removal of IVC ﬁlters in the Medicare population
from 1999 through 2008 [19]. Although IVC ﬁlters were often placed
not in accordance with established indications for their implantation,
the frequency of their use has doubled over the past decade and the
percentage of the removal was very low (ranging from 1.2%to 5.1%)
[15,19]. For these reasons, the FDA has recently echoed concerns
about the relative infrequency with which retrievable ﬁlters are re-
moved and has speciﬁcally recommended that “implanting physi-
cians and clinicians responsible for the ongoing care of patients
with retrievable IVC ﬁlters consider removing the ﬁlter as soon as
protection from PE is no longer needed” [20].
Different retrievable IVC ﬁlters
Results of the most important studies on retrievable ﬁlters are
reported in Table 1.
Gunther Tulip ﬁlter
The Gunther Tulip ﬁlter consists of four struts of stainless wheels
with hooks at the end acting as anchors. The ﬁlter can be placed either
from the femoral or the jugular access, and retrieval is from the right
jugular site [21]. The registry of the Canadian Interventional Radiolo-
gy Association [21] and several other reports [22–26] have demon-
strated the feasibility of retrieval of Gunther Tulip IVC device, after a
maximum implantation time of 139 days (mean 14 days), with a
low rate of recurrent PE while the ﬁlter was in place (0–3.6%); IVC
thrombosis occurred in 0–9.6% and retrieval was successful in most
of the cases (ranging from 88% to 98%).
ALN ﬁlter
The ALN ﬁlter is a hydrodinamic steel retrievable IVC ﬁlter. It has
six short legs that ensure its adherence to the IVC walls, and three
long legs that guarantee the correct central positioning into the
vena cava [27]. ALN ﬁlter can be placed from the femoral, brachial
or jugular vein approach, and can be retrieved only from the jugular
approach. A number of trials have investigated the efﬁcacy and safety
of long-term retrieval of the ALN device, showing a maximum im-
plantation time of 722 days (range 6–722 days) with a high rate of
retrieval technical success (range 78%-100%) [27–33].
Recovery ﬁlter
The Recovery Nitinol Filter (RNF) is composed of 12 nitinol wires
that extend from a nitinol sleeve and has six arms and six legs [34].
Efﬁcacy and safety of the Recovery Filter has been evaluated in
seven studies, demonstrating the feasibility of removal of the device
in a high percentage of patients (retrieval technical success varying
from 85% to 100%) with a maximum implantation time of 475 days
(range 5–475) [35–41].
OptEase ﬁlter
The OptEase ﬁlter is a nitinol-MRI compatible ﬁlter and it is the
only ﬁlter retrievable from a femoral vein approach; the ﬁlter has a
symmetrical double-basket design with six straights struts connecting
the proximal and distal baskets [42].
Several trials have recently investigated the efﬁcacy and safety of
retrieval of the OptEase device, showing a maximum implantation
time of 48 days (range 4–48 days) with a high percentage of removal
technical success (from 85% to 100%) [42–46].
Indications for ﬁlter implantation
Contraindications to anticoagulation
According to the 8th ACCP Evidence-Based Clinical Practice Guide-
lines on Antithrombotic and Thrombolytic Therapy [3,47], IVC ﬁlter
placement is recommended when there is a contraindication or com-
plication of anticoagulant therapy in a patient with proximal DVT or
PE. Frequently, the contraindication to anticoagulation is temporary
(i.e. haemorragic stroke, trauma) and antithrombotic therapy can be
started as soon as it is resolved; for this reason, retrievable IVC ﬁlters
may be the ideal “bridge” to anticoagulation for these patients. Main
indications for retrievable vena cava ﬁltration are reported in Table 2.
Table 1
Main results of retrievable ﬁlters studies.
Study Filter Number of ﬁlters
removed and placed
Mean duration between ﬁlter
placement and retrieval (days)
Retrieval technical
success (%)
Ponchon, 1999 [22] Gunther-Tulip 8 of 10 12; range 8–14 88
Millward, 2001 [21] Gunther-Tulip 52 of 91 9; range 2–25 98
Offner, 2003 [23] Gunther-Tulip 37 of 44 14; range 3–30 97
Asch, 2002 [35] Recovery 24 of 32 53; range 5–134 100
Pieri, 2003 [27] ALN 7 of 18 63; range 49–192 100
Barral, 2003 [28] ALN 13 of 54 22; range 11–90 100
Pancione, 2004 [29] ALN 28 of 96 72; range 30–120 100
Morris, 2004 [24] various 14 of 130 19; range 11–41 93
Imberti, 2005 [30] ALN 14 of 30 123; range 30–345 78
Grande, 2005 [36] Recovery 14 of 107 150; range 0–419 93
Oliva, 2005 [39] OptEase 21 of 27 11; range 5–14 100
Rosenthal, 2005 [43] OptEase 40 of 40 16; range 3–48 100
Ray, 2006 [26] various 80 of 197 19; range 1–139 85
Stefanidis, 2006 [37] various 47 of 83 142; range 17–475 87
Mismetti, 2007 [31] ALN 56 of 220 51; range 6–352 93
Karmy, 2007 [57] various 90 of 446 28.2±26.3 78
Pancione, 2006 [32] ALN 71of 276 74; range 30–130 93
Pellerin, 2008 [33] ALN 122 of 123 93; range 6–722 99
de Villiers, 2008 [38] Recovery 22 of 54 48; range 7–90 96
Oliva, 2008 [39] Recovery 51 of 120 53; range 7–242 100
Binkert 2009 [41] Recovery 61of 100 140; range 5–300 95
Onat, 2009 [45] OptEase 124 of 228 11; range 4–23 91
Kalva, 2011 [46] OptEase 14 of 71 9; range 5–21 85
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Trauma
Thromboprophylaxis is an important issue in patients with major
trauma [48], and PE is the cause of death in 20% of severely injured
patients [49]. Management of thromboprophylaxis may be problem-
atic because of the limited efﬁcacy of standard prevention (low dose
heparin, sequential compression devices) and concern about poten-
tial bleeding complications associated with anticoagulant treatment.
For these reasons, in the last few years an increasing interest in the
use of IVC ﬁlter for PE prophylaxis in this clinical setting has been
observed [47]. Unfortunately, there are no randomized trials demon-
strating a clear beneﬁt of IVC insertion in trauma patients [48–57].
Three small studies have reported a low rate of PE in patients with
severe polytrauma who underwent prophylactic IVC ﬁlter insertion
[54–56]. In a large prospective study 127multitrauma patients under-
went a prophylactic placement of a retrievable IVC ﬁlters (Gunther
Tulip n=49; Recovery n=41; OpTease n=37), without any complica-
tion [53]. Sixty-six patients underwent uneventful retrieval of IVC
ﬁlters after 5–116 days from implantation (mean 71 days), while in
45 retrieval was not attempted (41 due to contraindication to anticoa-
gulation and 4 because of trapped emboli within the ﬁlter). Finally, a
retrospective review of 446 trauma patients receiving retrievable IVC
ﬁlters in 21 different participating centers was performed (Gunther
Tulip n=152; Recovery n=224; OpTease n=37) [57]. Of interest,
only 22% of the implanted ﬁlters were retrieved; the main reason for
which IVC ﬁlters were not removed was because of loss to follow-up
(31%). Of 115 patients inwhom retrieval was attempted, removal failed
for technical reasons in 15 patients and because of signiﬁcant residual
thrombus within the ﬁlter in 10 patients.
Thrombolytic therapy
Systemic thrombolysis of proximal DVT and IVC thrombi has
resulted in several cases of fatal and non fatal PE; therefore, prophylactic
placement of IVC ﬁlters has been proposed as a strategy to prevent PE in
patients undergoing thrombolysis. A European multicenter registry of
temporary IVC ﬁlters used during systemic thrombolysis showed an
incidence of fatal PE of 2.1% and of non fatal PE of 1.6% [58]. To our
knowledge, no data have been published regarding retrievable IVC
ﬁlters during thrombolysis for DVT; because of their ease of use and
of their advantages, these devices appear as potentially attractive
alternatives to temporary ﬁlters. On the other hand, thrombolysis is
in principle contraindicated as a ﬁrst approach to DVT treatment [3],
thus the potential use of ﬁlters in this setting would be extremely
limited.
Pregnancy
The overall incidence of VTE complications during pregnancy
ranges from 0.2% to 1.2%, and is even higher during the puerperium
[59]. Since pregnancy is typically a temporary risk factor for VTE,
the use of a non-permanent ﬁlter is particularly appealing when
anticoagulation is contraindicated. In a multicenter study, about 3%
of all temporary ﬁlters inserted were placed in pregnant women
who were undergoing caesarean section and thrombectomy [60].
Few case reports showed that retrievable IVC ﬁlters offer a safe and
effective prevention to PE during pregnancy and puerperium and
can be removed without complications [61,62]. On the other hand,
there are no strong data supporting the routine use of IVC ﬁlters in
patients suffering from acute DVT during pregnancy and this device
should be reserved for selected and speciﬁc situations.
Major surgery associated with a high risk of DVT
Patients undergoing major orthopaedic surgery such as hip and
knee replacement carry a very high risk of VTE complications [47].
Several case series showed the efﬁcacy of IVC ﬁlters in the prevention
of PE in orthopaedic patients, but none of these studies included a
control group and follow-up was of limited intensity and duration
[29]. Furthermore many recent advances in pharmacological prophy-
laxis (low-molecular weight heparin, synthetic factor Xa and throm-
bin inhibitors) have contributed to signiﬁcantly reduce the risk of
VTE in this setting. Retrievable ﬁlters remain a useful option for high-
ly selected cases, i.e. patients at very high thromboembolic risk be-
cause of a previous, recent massive PE or recurrent VTE episodes or
patients with a major contraindication to pharmacologic therapy [30].
PE is considered the leading cause of death after bariatric surgery
and common pharmacologic prophylactic strategies have not been
adequately tested in morbidly obese patients [50,63]. Placement of
IVC ﬁlters has become a common prophylactic strategy among some
bariatric surgeons, even if no prospective randomized clinical trials
have compared IVC ﬁlters with alternative methods. However, ﬁlter
placement can be challenging in these patients, especially in the
super obese (BMI>60). In conclusion, there are no data supporting
the routine use of retrievable IVC ﬁlters in bariatric patients, and
this device should be reserved for speciﬁc situations.
Filter complications
The most important ﬁlter complications are reported in Table 3.
Filter occlusion and inferior vena cava thrombosis
Occlusion of the ﬁlter is the most frequent complication of vena
cava ﬁlters and its incidence varies from 6% to 30% of cases [16–19].
The reasons for this complication include thrombogenicity of the de-
vice, natural cephalic progression of DVT from the lower limb and en-
trapment of emboli within the ﬁlter. Thrombosis of the ﬁlter and vena
cava occlusion may be associated with important clinical side effects,
including decreased protection against PE, migration of the ﬁlter,
post-thrombotic syndrome and chronic venous stasis. New genera-
tion ﬁlters offer the advantage of a lower thrombogenicity compared
with older ones.
Lower extremity vein thrombosis and post-thrombotic syndrome
Vena cava ﬁlters themselves have sometimes been observed to
obstruct blood ﬂow and contribute to an increase of recurrence of
DVT of the lower extremity [8,10,64]. For these reason, the ACCP
guidelines recommend, if the ﬁlter is positioned as an alternative to
Table 2
Indications for retrievable IVC ﬁlters implantation.
Appropriate indication
Temporary contraindication to anticoagulation
Potential indications
Prophylaxis in high risk trauma patients
Thrombolysis of ilio-caval thrombus
Pregnancy
Prophylaxis in high risk major orthopedic surgery
Prophylaxis in bariatric surgery
Table 3
Main complications of inferior vena cava ﬁlters.
Complication Rate (%)
Complications from insertion 4–11
Insertion site thrombosis 2–28
IVC thrombosis 6–30
Filter migration 3–69
IVC perforation 9–24
Post-thrombotic syndrome 5–70
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anticoagulation, beginning of adequate anticoagulant therapy as soon
as possible if the risk of bleeding resolves [3]. Otherwise, the optimal
duration of anticoagulation in patients with permanent or optional
ﬁlter that is left in situ is still uncertain. A recently published cohort
study followed patients who had VTE, followed by treatment with
permanent IVC ﬁlter placement and were anticoagulated long-term
as soon as safety allowed [64]. Patients underwent annual physical
examinations and ultrasound surveillance of the lower extremity
deep veins and of the IVC ﬁlter site. Symptomatic DVT occurred in
24 of 121 patients (20%; 95% CI, 14%-28%); symptomatic PE (one
fatal) was diagnosed in six patients (5%; 95% CI, 2%-10%). There
were 45 episodes of ﬁlter clot in 36 patients (30%; 95% CI, 22%-38%).
The rate of major bleeding (6.6%) was similar to that of a concurrent
persistently anticoagulated cohort without IVC ﬁlters (5.8%). Thus,
the authors suggest indeﬁnite anticoagulation to IVC ﬁlter recipients
if contraindications to anticoagulation remit. On the contrary, other
data of the literature, although limited, do not seem to show signiﬁcant
differences in the risk of DVT recurrences after IVC ﬁlter placementwith
or without anticoagulation [65]. To sum up, in absence of strong
evidence in the literature and waiting for the results of well-designed
clinical trials, patients with IVC ﬁlter should receive anticoagulation
therapy according to current guidelines in any speciﬁc clinical situation;
it is not suggested to continue indeﬁnite anticoagulation just because
the ﬁlter is still present.
Finally, the association of vena cava ﬁlters with an increase of
post-thrombotic syndrome is still matter of debate; the available
data suggest the potential risk of post-thrombotic syndrome during
long-term follow-up in patients with permanent IVC ﬁlters [8,10].
Vena cava perforation
Vena cava perforation is a usually asymptomatic complication, and
without substantial clinical importance. Frequently, it is only a radio-
logical ﬁnding which occurs when ﬁlter components extend more
than 3 mm outside of the wall of the IVC [64]. More rarely, bleeding
complications are associated with vena cava perforation, usually
when the ﬁlter leg is withdrawn leaving an open hole; other severe
consequences have been rarely reported [66,67].
Filter migration
The migration of the ﬁlter towards the heart is a potentially life-
threatening complication of IVC ﬁlters, even if, in the majority of
cases, migration is minor and does not result in any signiﬁcant mor-
bidity [30]. A multicenter registry found that temporary IVC ﬁlters
had a dislocation rate of 4.8%; no death due to this complication
was reported [58]. A recently published paper reported a high rate
of strut fracture (16%) and fragments embolization (25%) of the
Bard retrievable IVC ﬁlter; of interest, three out of 28 patients experi-
enced life-threatening cardiac complications related to migration of
fragments to the heart [18].
Superior vena cava ﬁlters
The placement of superior vena cava (SVC)ﬁlters to prevent PE from
upper-extremity DVT (UEDVT), although controversial, has been
reported. A recently published review identiﬁed a total of 21 publica-
tions that included 209 SVC ﬁlters and documented eight major ﬁlter-
related complications (3.8%), including four cardiac tamponades,
two aortic perforations, and one recurrent pneumothorax [68]. The in-
hospital or 1-month mortality rate was 43.1%. Twenty-eight additional
publications were identiﬁed which reported 3,747 cases of UEDVT.
The rates of PE and associatedmortality were 5.6% and 0.7%, respective-
ly. Studies imaging both upper and lower extremities found DVT 14.7
times more likely to occur in the lower extremities than in the upper
extremities and the rate of PE from a lower-extremity thrombus to be
25.1%. The lack of evidence documenting the risk from UEDVT and the
absence of data supporting the safety and efﬁcacy of SVC ﬁlters bring
their beneﬁt into question.
Catheter Directed Thrombolysis
Deep vein thrombosis
Treatment of lower limb DVT should be started as soon as possible
to maximally reduce the risk of further complications such as PE,
recurrent DVT or post-thrombotic syndrome (PTS) [69]. PTS occurs
in 20 to 50% of patients after acute DVT and leg ulceration is present
in up to 10% of patients [70,71]. These conditions lead to disability
and reduced quality of life, with important clinical and public health
implications, as more than 50% of patients are of working age. Oral
anticoagulant therapy reduces thrombus propagation, but does not
effectively produce clot lysis, thus potentially resulting in an incomplete
prevention of PTS, which occurs after proximal DVT in up to 50% of
patients within two years [70,71]. Treatments that actively remove
the clots have the potential to reduce acute symptoms and the risk of
PTS by directly reversing venous obstruction and restoring the function
in valves that were immobilized by the thrombus.
The effectiveness of systemic thrombolysis to achieve early clot
lysis had been investigated in a number of trials which found it to
be associated with high rates of serious bleeding complications with
relatively modest rates of thrombus clearance [72–74]. Catheter-
directed thrombolysis (CDT) involves delivery of thrombolytic agents
directly through a catheter traversing the thrombus. This may be
more effective in achieving local clot lysis and in restoring venous
patency while signiﬁcantly reducing the risk of systemic bleeding
complications.
Most of the studies on catheter-directed thrombolysis are obser-
vational studies or case-series [75–83]. The long-term outcome of
catheter-directed thrombolysis in patients with acute iliofemoral
venous thrombosis was evaluated in 101 patients with 103 extremi-
ties affected by iliofemoral venous thrombosis [84]. At 6 years, 82%
of the limbs treated with CDT had patent veins with competent valves
and without any skin changes or venous claudication. In the National
Venous Registry, patients with short-term thrombosis (b10 days) had
better outcomes than those with older clots and correction of under-
lying venous lesions after successful thrombolysis, usually with
intravascular stenting, appeared to be beneﬁcial [76]. In an evaluation
of 98 patients with iliofemoral DVT treated with CDT (n=68) or antic-
oagulation (n=30), quality of life was better in patients treated with
CDT and correlated with the degree of lysis [81].
Few trials compared catheter-directed thrombolysis with conven-
tional anticoagulant treatment. A single-center trial [85] randomly se-
lected 35 patients with acute iliofemoral DVT to catheter-directed
intrathrombus streptokinase or to anticoagulation alone. Six-months
after treatment, patency rate was signiﬁcantly higher in the throm-
bolysis group (72% vs 12%, pb0.001), and the prevalence of venous
reﬂux was lower. In a subsequent, multicenter, controlled trial, 103
patients were allocated to additional CDT (n=50) or to standard
treatment alone (n=53) [86]. After CDT, complete lysis was achieved
in 24 and partial (50%-90%) lysis in 20 patients. After 6 months, iliofe-
moral patency was found in 32 (64.0%) in the CDT group vs. 19
(35.8%) controls, corresponding to an absolute risk reduction (RR)
of 28.2%. Although bleeding complications are the major concern
with lytic therapy, recent reports have shown bleeding complication
rates to be less than half the rates in earlier reports, which is likely
due to more appropriate patient selection and experience with the
technique. Data are not available for the comparison between differ-
ent plasminogen activators or between a particular catheter or
catheter-based technique to others, and there are insufﬁcient data
to assess the additional beneﬁts of IVC ﬁlters in this setting. Overall,
the results of published studies suggest that CDT may be effective in
selected patients; however, indications for CDT are mainly based on
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the results of few and small RCTs. Thus, the latest ACCP guidelines
suggest CDT only in selected patients with extensive acute proximal
DVT (iliofemoral DVT, symptoms forb14 days, good functional status,
life expectancy>1 year) who have a low risk of bleeding, if appropri-
ate expertise and resources are available [3].
Pulmonary embolism
It has been postulated that direct, intra-embolic infusion of throm-
bolytics into large proximal emboli might be more beneﬁcial than the
peripheral route. In patients with acute PE, thrombolytic therapy ad-
ministered directly into the pulmonary arteries does not appear to be
more beneﬁcial than that given by peripheral administration, and in-
fusion of rt-PA directly into a pulmonary artery as opposed to a pe-
ripheral vein does not accelerate thrombolysis, but causes more
frequent bleeding at the catheter insertion site. In fact, the results
from a pilot trial indicate that intrapulmonary infusion of rt-PA does
not offer signiﬁcant beneﬁt over the intravenous route [87]. When a
lytic agent is appropriate for PE, current evidence supports that
thrombolytic therapy should be infused into a peripheral vein over
2 hours or less; in particular, rt-PA administered at a dose of 100 mg
over 2 hours, is currently the most widely used and evaluated regi-
men. Based on the available literature, the last guidelines of the
ACCP recommend that in patients with acute PE, thrombolytic treat-
ment should be administered via a peripheral vein rather than plac-
ing a pulmonary artery catheter [3].
Thrombosuction
Deep vein thrombosis
The combination of mechanical thrombus fragmentation (associ-
ated or not with suction) and catheter-directed thrombolysis (CDT)
is frequently used in the daily clinical practice of centers performing
CDT (pharmacomechanical thrombolysis). Although randomized clini-
cal trials comparing CDT and pharmacomechanical thrombolysis are
not available, retrospective data [88,89] show that the two proce-
dures have similar efﬁcacy and safety based on the rates of successful
thrombolysis and of major bleeding, respectively. However, pharma-
comechanical thrombolysis is associated with shorter treatment
times, fewer days of hospitalization and is less expensive.
Based on the available literature, the latest guidelines of the ACCP
suggest in patients with acute DVT the use of pharmacomechanical
thrombolysis (including thrombus fragmentation and/or suction) in
preference to CDT alone, with the aim to shorten treatment time if ap-
propriate expertise and resources are available [3]. Actually, large and
well-designed randomized clinical trials assessing the role of CDT and
mechanical thrombectomy for reducing the incidence of post-
thrombotic syndrome in patients with DVT are still ongoing (AT-
TRACT, CaVenT and DUTCH CAVA trials). However, waiting the results
of these studies, pharmacomechanical thrombolyis should be used
only in appropriate patients who do not have any contraindications
to thrombolysis (Table 4).
Pulmonary embolism
Hemodynamically unstable PE, deﬁned as PE with arterial hypoten-
sion or cardiogenic shock at presentation, is associatedwith a poor short
termprognosis. Systemic thrombolysis is themainstay of therapy in this
setting, but its use remains associated with an estimated 20% risk of
major hemorrhage, including a 3%-5% risk of hemorrhagic stroke. Al-
though rarely performed, surgical embolectomy is a potential alterna-
tive treatment. However, the presence of contraindications to
ﬁbrinolytic therapy are rather common in the setting of high-risk PE,
and surgical embolectomy is frequently not performed owing to exces-
sively high surgical risk. Under those circumstances, interventional
catheterization techniques (including percutaneous, catheter-based
thrombectomy, thrombus fragmentation, clot pulverization, rheolytic
thrombectomy, and rotational catheter embolectomy) [90–94] are
reasonable alternatives for hemodynamically unstable PE. Pharmaco-
logic thrombolysis and mechanical interventions can also be done
together in absence of high bleeding risk.
There are no randomized clinical trials or prospective well con-
ducted cohort studies that have evaluated the efﬁcacy and safety of
interventional catheterization techniques in this clinical setting. Several
case series [90–93] enrolling a small number of patients suggest that
these techniques can be lifesaving in very selected clinical situations.
A recently published meta-analysis evaluated the safety and efﬁcacy
of modern catheter-directed treatment (CDT) for the therapy of
massive PE [95]. Modern techniques were deﬁned, as the use of low-
proﬁle devices (b or =10 F), mechanical fragmentation and/or aspira-
tion of emboli including rheolytic thrombectomy, and intraclot throm-
bolytic injection if a local drug was infused. Clinical success was
deﬁned as stabilization of hemodynamics, resolution of hypoxia, and
survival to hospital discharge. Five hundred and ninety-four patients
from 35 studies (six prospective, 29 retrospective) met the criteria for
inclusion. For mechanical intervention, the most common technique
used was rotating pigtail fragmentation of emboli, performed in 69%
of the patients (408/594). The pooled clinical success rate from CDT
was 86.5% (95% conﬁdence interval [CI]: 82.1%, 90.2%). Pooled risks of
minor and major procedural complications were 7.9% (95% CI: 5.0%,
11.3%) and 2.4% (95% CI: 1.9%, 4.3%), respectively. Data on the use of sys-
temic thrombolysis before CDT were available in 571 patients; 546 of
those patients (95%) were treatedwith CDT as a ﬁrst adjunct to heparin
without previous intravenous thrombolyis. The latest guidelines of the
ACCP recommend that interventional catheterization techniques
should not be used for most patients with PE; this approach is reason-
able only if appropriate expertise is available in selected highly compro-
mised patients who are unable to receive thrombolytic therapy because
of bleeding risk, or whose critical status does not allow sufﬁcient time
for systemic thrombolytic therapy to be effective [3].
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